Does Rallies show Form 4 insider transactions for MIRM?

Yes. Rallies tracks MIRM insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is MIRM research on Rallies investment advice?

No. Rallies provides research, data, and educational context for MIRM. It does not provide personalized investment advice.

MIRM (Mirum Pharmaceuticals, Inc. Common Stock) Stock Analysis - Insider Trades

Mirum Pharmaceuticals, Inc. Common Stock (MIRM) is a publicly traded Healthcare sector company. As of May 21, 2026, MIRM trades at $96.95 with a market cap of $5.82B and a P/E ratio of -7.07. MIRM moved +1.44% today. Year to date, MIRM is +28.31%; over the trailing twelve months it is +113.83%. Its 52-week range spans $36.88 to $114.99. Analyst consensus is strong buy with an average price target of $146.00. Rallies surfaces MIRM's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading MIRM stock inside the company?

Recent MIRM insider activity includes Ramasastry Saira sold 2.00K, Ramasastry Saira sold 2.00K, BJERKHOLT ERIC sold 7.29K, Quan Joanne sold 7.29K, and Ramasastry Saira sold 2.00K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

MIRM Key Metrics

Key financial metrics for MIRM
Metric	Value
Price	$96.95
Market Cap	$5.82B
P/E Ratio	-7.07
EPS	$-13.61
Dividend Yield	0.00%
52-Week High	$114.99
52-Week Low	$36.88
Volume	465
Avg Volume	0
Revenue (TTM)	$569.61M
Net Income	$-798.84M
Gross Margin	0.00%

Recent MIRM Insider Trades

Ramasastry Saira sold 2.00K (~$218.94K) on May 15, 2026.
Ramasastry Saira sold 2.00K (~$193.80K) on Apr 15, 2026.
BJERKHOLT ERIC sold 7.29K (~$670.24K) on Mar 16, 2026.
Quan Joanne sold 7.29K (~$670.24K) on Mar 16, 2026.
Ramasastry Saira sold 2.00K (~$181.52K) on Mar 16, 2026.

Latest MIRM News

Mirum prices $600M 2032 convertible notes to refinance 2029 converts — May 13, 2026
Mirum rises as volixibat Phase 2b VISTAS win keeps biotech bid alive — May 6, 2026
Mirum Pharmaceuticals’ Volixibat Trial Success Spurs $140 Price Target, 9.6% Share Jump — May 5, 2026
Mirum dips despite VISTAS volixibat Phase 2b win; investors digest details — May 4, 2026
Mirum jumps as analysts lift targets ahead of multiple 2026 trial catalysts — Apr 30, 2026

MIRM Analyst Consensus

11 analysts cover MIRM: 0 strong buy, 11 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $146.00.

Common questions about MIRM

Who is trading MIRM stock inside the company?: Recent MIRM insider activity includes Ramasastry Saira sold 2.00K, Ramasastry Saira sold 2.00K, BJERKHOLT ERIC sold 7.29K, Quan Joanne sold 7.29K, and Ramasastry Saira sold 2.00K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for MIRM?: Yes. Rallies tracks MIRM insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is MIRM research on Rallies investment advice?: No. Rallies provides research, data, and educational context for MIRM. It does not provide personalized investment advice.